On October 9, WUXI BIO fell 3.14% in regular trading, trading at HK$52.4, with turnover of HK$49.35 billion.

The Hong Kong biotech sector extended its previous session's pullback, with CXO concept stocks broadly under pressure as short-term profit-taking persisted. The Hang Seng Biotech Index had dropped 3.15% on October 7, and Genscript Biotech plunged over 14%, dampening sentiment toward WUXI BIO. Despite solid mid-year results showing revenue of RMB11.787 billion, adjusted net profit of RMB3.937 billion, and gross margin improving to 46.2%, some investors locked in gains following the sector-wide recovery since June, intensifying the correction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)